Molnupirvir-induced SARS-CoV-2 mutagenesis mechanism and results of this antiviral in patients affected by COVID-19
DOI:
https://doi.org/10.33448/rsd-v10i15.22916Keywords:
SARS-CoV-2; COVID-19; Antiviral; Molnupiravir.Abstract
Introduction: Antiviral drugs often target viral polymerases and function as nucleoside analogues that terminate the elongation of the RNA chain. However, such chain-terminating antivirals are generally not effective against SARS-CoV-2, as coronaviruses carry an exonucleolytic proofreading activity, which can thus remove improperly incorporated nucleotides from the ends of RNAs. Objective: to elucidate the mutagenic mechanisms of SARS-CoV-2 induced by molnupirvir, as well as to couple the results of the use of this antiviral in patients affected by COVID-19. Methodology: This is a systematic literature review and the following keywords were crossed: "molnupiravir", "COVID-19", "SARS-CoV-2", "antiviral", "RNA" in the following bases data: National Library of Medicine (PubMed MEDLINE), Scientific Electronic Library Online (Scielo), Cochrane Database of Systematic Reviews (CDSR), Google Scholar, Virtual Health Library (VHL) and EBSCO Information Services. Relevant sources inherent to the theme were analyzed, using as one of the main criteria the choice of current, original and international articles. After careful reading of the publications, 4 articles were not used due to the exclusion criteria. Thus, there were a total of 12 scientific articles for review. Results: Molnupiravir or NHC can increase G to A and C to U transition mutations in coronavirus replication. These increases in mutation frequencies may be associated with increases in antiviral effects; however, no biochemical data of molnupirvir-induced mutagenesis have been reported. Here we study the effects of the active compound NHC 5'-triphosphate (NHC-TP) against the purified severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase complex. In addition, molnupiravir has demonstrated in vitro activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultures of human airway epithelial cells. Conclusion: a promising candidate for the treatment of these patients is molnupiravir (or EIDD-2801), which also targets RdRp of SARS-CoV-2, interferes with virus replication, inhibiting SARS-CoV-2 replication in tissue human lung and blocking its transmission.
References
Abdelnabi, R., et al. (2021). O tratamento combinado de mulnupiravir e favipiravir resulta em potenciação marcada da eficácia antiviral em um modelo de infecção de hamster SARS-CoV-2. bioRxiv, 1-4.
Cox, R. M., et al. (2021). O análogo de ribonucleosídeo administrado terapeuticamente MK-4482 / EIDD-2801 bloqueia a transmissão de SARS-CoV-2 em furões. Nat. Microbiol., 6 (7), 11-18.
Gordon, C. J., et al. (2021). Molnupiravir promove SARS-CoV-2 mutagenesis via o RNA template. J Biol Chem, 297 (8), 177-187.
Kabinger, F., et al. (2021). Mecanismo de mutagênese de SARS-CoV-2 induzida por molnupiravir. Struct Mol Biol., 28 (9), 740-746
Malone, B., et al. (2021). Molnupiravir: codificação para catástrofe. Nature Structural & Molecular Biology, 28 (7), 706-708.
Mehase, E., et al. (2021). Molnupiravir reduz o risco de admissão hospitalar em 50% em pacientes em risco. The BMJ, 375 (22), 1-4.
Naydenova, K., et al. (2021). Estrutura da RNA polimerase dependente de RNA da SARS-CoV-2 na presença de favipiravir-RTP. Proc. Nat Acad. Sci., 118 (20), 1-17.
Prainter W. P., et al. (2021). Segurança humana, tolerabilidade e farmacocinética do molnupiravir, um novo agente antiviral oral de amplo espectro com atividade contra SARS-CoV-2. Química de agentes antimicrobianos, 65 (48), 1-10.
Prainter, W. P., et al. (2021). Redução de SARS-CoV-2 infeccioso no estudo de tratamento de COVID-19 com molnupiravir. Retroviruses and Opportunistic Infections, 6 (10), 1-5.
Sheahan, T. P., et al. (2020). Um antiviral de amplo espectro com biodisponibilidade oral inibir o SARS-CoV-2 em culturas de células epiteliais das vias aéreas humanas e múltiplos coronavírus em camundongos. Sci Med., 12 (8), 1-6.
Teoh, S. L., et al. (2020). Antivirais de ação direta para COVID-19. Frontiers in Microbiology, 11 (18), 57-71.
Zhou, S., et al. (2021). β- D - N 4 -hidroxicitidina (NHC) inibe SARS-CoV-2 por mutagênese letal, mas também é mutagênico para células de mamíferos. J. Infect. Dis., 224 (3), 9-13.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Gabriel dos Reis Rodrigues Silva; Bárbara Queiroz de Figueiredo; Rúbia Carla Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
